ENDO 09 Session Library Webcast: Multidisciplinary Approach to Management of Neuroendocrine Tumors
ACCREDITATION
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Special Program Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.
DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.
LEARNER OBJECTIVES
Upon completion of this educational activity, participants will be able to:
TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to endocrinologists and other healthcare professionals involved in the treatment and management of neuroendocrine tumors.
DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: Matthew H. Kulke, MD has received consulting fees from Novartis.
The following SPC members who planned and/or reviewed content for this activity reported relevant financial relationships: Laurence Katznelson, MD has received speaker honoraria from Tercica and research grant support from Novartis.
The following faculty reported no relevant financial relationships: Wouter W. de Herder, MD, PhD; Anthony P. Heaney, MD, PhD; Anju Sahdev, MBBS, MRCP, FRCR.
Endocrine Society staff associated with the development of this program reported no relevant financial relationships.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires that this information be disclosed to the learners at the beginning of the presentation.
Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:
To receive AMA PRA Category 1 Credits™, the learner should:
Last Review Date: August 25, 2010
Activity Release/Expiration Dates: June 26, 2009 through September 7, 2011For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or vparcan@endo-society.org.